drugset / Trial / NCT06888973

Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases

NCT06888973

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group). The primary outcome measures will be clinical improvement based on the respective disease specific clinical scores, normalization of T-lymphocyte subsets and \> 50% reduction in disease specific antibody titres. The study will also document the type and frequency of any adverse event or side effects, reported by or seen in any of the trial participants. Patients in treatment group will receive single session of MSC therapy and placebo group will receive 0.9% saline solution. The participants will be followed at 3 and 6 months.

Timeline

Start
2025-02-01
Primary completion
2025-02-01
Completion
2026-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy